<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02205762</url>
  </required_header>
  <id_info>
    <org_study_id>13-428</org_study_id>
    <secondary_id>2011-001699-20</secondary_id>
    <secondary_id>042011</secondary_id>
    <nct_id>NCT02205762</nct_id>
  </id_info>
  <brief_title>LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis</brief_title>
  <official_title>LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>North American Consortium for Histiocytosis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Histiocyte Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>North American Consortium for Histiocytosis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The LCH-IV is an international, multicenter, prospective clinical study for pediatric
      Langerhans Cell Histiocytosis LCH (age &lt; 18 years).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The international efforts of the past 20 years have shown that combination therapy with
      vinblastine and prednisone is an effective therapy for Multi-system (MS)-LCH. The previous
      prospective trial LCH-III confirmed this regimen as a standard regimen for MS-LCH in patients
      with and without risk organ involvement. It also showed that prolonged treatment in the
      latter group (treatment duration of 12 vs. 6 months) is superior in preventing disease
      reactivations. The results of this trial are encouraging and serve as a basis for the LCH-IV
      study design.Due to the complexity of the disease presentations and outcomes, the LCH-IV
      study seeks to tailor treatment based on features at presentation and on response to
      treatment, leading to seven strata:

        -  Stratum I: First-line treatment for MS-LCH patients (Group 1) and patients with Single
           system (SS)-LCH with multifocal bone or &quot;Central Nervous System (CNS)-risk&quot; lesions
           (Group 2)

        -  Stratum II: Second-line treatment for non-risk patients (patients without risk organ
           involvement who fail first-line therapy or have a reactivation after completion of
           first-line therapy)

        -  Stratum III: Salvage treatment for risk LCH (patients with dysfunction of risk organs
           who fail first-line therapy)

        -  Stratum IV: Stem cell transplantation for risk LCH (patients with dysfunction of risk
           organs who fail first-line therapy)

        -  Stratum V: Monitoring and treatment of isolated tumorous and neurodegenerative CNS-LCH

        -  Stratum VI: Natural history and management of &quot;other&quot; SS-LCH (patients who do not need
           systemic therapy at the time of diagnosis)

        -  Stratum VII: Long-term Follow up (all patients irrespective of previous therapy will be
           followed for reactivation or permanent consequences once complete disease resolution has
           been achieved and the respective protocol treatment completed)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients with Reactivation Free Survival</measure>
    <time_frame>12 Months</time_frame>
    <description>Stratum I, II, VI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Response Rate of Second Cycle</measure>
    <time_frame>9 weeks</time_frame>
    <description>Stratum III</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall and disease free survival at 1 and 3 years after reduced intensity conditioning hematopoietic stem cell transplantation (RIC-HSCT)</measure>
    <time_frame>3 Years</time_frame>
    <description>Stratum IV</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The cumulative incidence of radiological and clinical neurodegeneration in patients with isolated tumorous CNS-LCH, DI, anterior pituitary dysfunction, and those with CNS-risk lesions</measure>
    <time_frame>2 Years</time_frame>
    <description>Stratum V</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The time interval and cumulative incidence of progression of radiological neurodegeneration to clinically manifested ND-CNS-LCH</measure>
    <time_frame>2 Years</time_frame>
    <description>Stratum V</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative incidence of specific Permanent Consequences e.g. diabetes insipidus (DI), growth hormone deficiency (GHD), neuropsychological impairment, etc.</measure>
    <time_frame>2 Years</time_frame>
    <description>From all treatment stratum via long-term follow up in Stratum VII</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 Years</time_frame>
    <description>Stratum I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Serious and Non-Serious Adverse Events</measure>
    <time_frame>2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Permanent Consequences</measure>
    <time_frame>2 Years</time_frame>
    <description>All Stratum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of reactivations in risk organs</measure>
    <time_frame>2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to complete disease resolution</measure>
    <time_frame>2 Years</time_frame>
    <description>Stratum III</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate to the combination of prednisone, vincristine and cytarabine</measure>
    <time_frame>2 years</time_frame>
    <description>Stratum II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients alive and free of disease without permanent consequences (e.g. diabetes insipidus, anterior pituitary dysfunction, radiological or clinical neurodegeneration)</measure>
    <time_frame>2 Years</time_frame>
    <description>Stratum II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of treatment-related toxicities</measure>
    <time_frame>2 Years</time_frame>
    <description>Stratum II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reactivation rates after continuation treatment with Indomethacin vs. 6-MP/MTX.</measure>
    <time_frame>2 years</time_frame>
    <description>Stratum II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The type of subsequent intensive and/or maintenance therapy utilized</measure>
    <time_frame>2 Years</time_frame>
    <description>Stratum III</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early and late mortality</measure>
    <time_frame>2 Years</time_frame>
    <description>Stratum II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early and late toxicity</measure>
    <time_frame>2 Years</time_frame>
    <description>Stratum III</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>d+100 transplant related mortality</measure>
    <time_frame>2 Years</time_frame>
    <description>Stratum IV</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hematopoietic recovery, and donor chimerism at d+100 and 1 year post RIC-HSCT</measure>
    <time_frame>2 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Record all occurrence of skin, GI or liver abnormalities fulfilling criteria of Grades II-IV acute GVHD</measure>
    <time_frame>2 Years</time_frame>
    <description>Stratum IV: Hematopoetic Stem Cell Transplantation for Risk LCH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with incidence of chronic GVHD</measure>
    <time_frame>2 Years</time_frame>
    <description>Stratum IV</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate to ND-CNS-targeted therapy at 12 and 24 months after start of therapy</measure>
    <time_frame>2 years</time_frame>
    <description>Stratum V</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response of isolated tumorous CNS-LCH to 2-CDA</measure>
    <time_frame>2 Years</time_frame>
    <description>Stratum V</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of ND-CNS-LCH in patients with isolated tumorous CNS-LCH</measure>
    <time_frame>2 Years</time_frame>
    <description>Stratum V</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Methods of early identification of ND-CNS-LCH</measure>
    <time_frame>2 Years</time_frame>
    <description>Stratum V - Exploration of the value of neurochemistry, neurophysiology, and neuropsychology methods in early identification of ND-CNS-LCH and in assessing its severity, and comparison to MRI findings.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for systemic therapy later during disease course</measure>
    <time_frame>2 Years</time_frame>
    <description>Stratum VI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identify possible risk factors for permanent consequences (PC)</measure>
    <time_frame>2 Years</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">1100</enrollment>
  <condition>Langerhans Cell Histiocytosis</condition>
  <arm_group>
    <arm_group_label>Stratum I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stratum I The combination of Prednisone and vinblastine is the standard first-line combination for patients needing systemic therapy (Stratum I). Patients with MS-LCH and involvement of risk organs, who do not respond to 6-12 weeks of standard therapy, will be immediately switched to alternative treatment approaches (Stratum III or Stratum IV).
Further therapy prolongation (12 vs. 24 months) and intensification (± mercaptopurine) will further reduce the reactivation rate and the permanent consequences.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stratum II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A uniform &quot;intensive&quot; 24-week course consisting of prednisolone, vincristine and cytosine-arabinoside will be introduced in Stratum II for eligible patients. It will be followed by a continuation therapy to total treatment duration of 24 months. Participants who after SL-IT (week 24) have a response (NAD or AD better) are eligible for randomization between the continuation arms &quot;INDOMETHACIN&quot; and &quot;6-MP/MTX&quot; (mercaptopurine and Methotrexate).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stratum III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Salvage treatment for risk LCH To assess the efficacy of the combination 2-CdA/Ara-C (Cytosine Arabinoside and 2-chlorodeoxyadenosine) in MS-LCH (patients with risk organ involvement, who fail to respond to front-line (Stratum I) therapy.
The initial therapy consists of 2 courses of 2-CdA/Ara-C. Continuation of outlined treatment to be assessed at assigned intervals in each stratum.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stratum IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To determine the overall and disease free survival at 1 and 3 years after reduced intensity conditioning hematopoietic stem cell transplantation (RIC-HSCT). Salvage treatment option for MS-LCH patients with risk organ involvement, who fail to respond to front-line therapy (Stratum I) OR to the salvage 2- CdA/Ara-C regimen (Stratum III).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stratum V</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stratum V Monitoring and Treatment of isolated tumorous and neurodegenerative CNS-LCH
- Special regimens will be offered to patients with isolated tumorous CNS-LCH (repeated 2-CdA courses) and to patients with clinically manifested ND-CNS-LCH (+/- extracranial LCH manifestations). For the last group monotherapy with Ara-C courses or (Intravenous immunoglobulin)IVIG will be offered depending on physician's choice.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stratum VI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Natural history and management of &quot;other&quot; SS-LCH not eligible for stratum I group 2.
Treatment Options- Management (mostly &quot;wait &amp; see&quot; and topical treatment) is left to the discretion of the treating physician. All treatments and disease responses must be reported in the database. In the case of uncertainties please contact your National Coordinator.
Patients being followed on Stratum VI who have progression of disease to MSLCH, multifocal bone disease or CNS-risk bone lesions should be enrolled on Stratum I therapy.
Patients being followed on Stratum VI who develop isolated tumorous or neurodegenerative CNS-LCH should be enrolled on Stratum V.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Stratum I</description>
    <arm_group_label>Stratum I</arm_group_label>
    <arm_group_label>Stratum II</arm_group_label>
    <arm_group_label>Stratum VI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinblastine</intervention_name>
    <description>Stratum I</description>
    <arm_group_label>Stratum I</arm_group_label>
    <arm_group_label>Stratum II</arm_group_label>
    <arm_group_label>Stratum VI</arm_group_label>
    <other_name>Velban®</other_name>
    <other_name>Vincaleukoblastine Sulfate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mercaptopurine</intervention_name>
    <description>Stratum I</description>
    <arm_group_label>Stratum I</arm_group_label>
    <arm_group_label>Stratum II</arm_group_label>
    <arm_group_label>Stratum VI</arm_group_label>
    <other_name>-Purinethol®</other_name>
    <other_name>-6-MP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INDOMETHACIN</intervention_name>
    <description>Indomethacin fixed dose given daily orally in two divided doses with gastric protection for total treatment duration of 24 months.</description>
    <arm_group_label>Stratum II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>fixed dose weekly orally for total treatment duration of 24 months.</description>
    <arm_group_label>Stratum II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytosine Arabinoside</intervention_name>
    <arm_group_label>Stratum II</arm_group_label>
    <arm_group_label>Stratum V</arm_group_label>
    <arm_group_label>Stratum VI</arm_group_label>
    <other_name>Cytarabine, Ara-C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2-chlorodeoxyadenosine</intervention_name>
    <arm_group_label>Stratum III</arm_group_label>
    <arm_group_label>Stratum V</arm_group_label>
    <arm_group_label>Stratum VI</arm_group_label>
    <other_name>2-CdA</other_name>
    <other_name>Cladribin®</other_name>
    <other_name>Leustatin®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>hematopoietic stem cell transplantation (RIC-HSCT)</intervention_name>
    <arm_group_label>Stratum IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Intravenous immunoglobulin</intervention_name>
    <arm_group_label>Stratum V</arm_group_label>
    <arm_group_label>Stratum VI</arm_group_label>
    <other_name>IVIG</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stratum I

               -  Patients must be less than 18 years of age at the time of diagnosis.

               -  Patients must have histological verification of the diagnosis of Langerhans cell
                  histiocytosis according to the criteria described in Section 6.1

               -  Signed informed consent form

          -  Stratum II

               -  Patients of Stratum I who have:

               -  Progressive disease (AD worse) in non-risk organs after 6 weeks (Initial Course

               -  AD intermediate or worse in non-risk organs or AD better in risk organs after 12
                  weeks (Initial Course 2)

               -  Disease progression (AD worse) in non-risk organs at any time during continuation
                  treatment

               -  Active disease at the end of Stratum I treatment

               -  Disease reactivation in non-risk organs at any time after completion of Stratum I
                  treatment

          -  Stratum III

               -  Patients from Stratum I who fulfill the following criteria:

               -  AD worse in risk organs after week 6 (after Initial Course 1), or AD worse or AD
                  intermediate in risk organs after week 12 (after Initial Course 2).

               -  Presence of unequivocally severe organ dysfunction at the above mentioned
                  evaluation points (hematological dysfunction, liver dysfunction, or both of them)
                  as

                    -  Hb &lt;70 g/L (&lt;7.0 g/dl) and/or transfusion dependency

                    -  PLT &lt;20 x109/L (20,000/μL) and/or transfusion dependency (both criteria have
                       to be fulfilled) AND/OR

                    -  Liver dysfunction (or digestive involvement with protein loss)

                    -  Total protein &lt;55 g/L or substitution dependency

                    -  Albumin &lt;25 g/L or substitution dependency (at least one of the two criteria
                       to be fulfilled)

          -  Stratum IV

               -  Patients from Stratum I or Stratum III who fulfill the following criteria:

               -  AD worse in risk organs after week 6 (after Initial Course 1), or AD worse or AD
                  intermediate in risk organs after week 12 (after Initial Course 2) of Stratum I
                  OR

               -  AD worse after the 2nd and 3rd 2-CdA/Ara-C course, and those AD worse or AD
                  intermediate after the 4th 2-CdA/Ara-C course of Stratum III AND

               -  Presence of unequivocally severe organ dysfunction at the above mentioned
                  evaluation points (hematological dysfunction, liver dysfunction, or both of them)
                  as defined in Table XI (see Section 10.3.1).

               -  Informed consent: All patients or their legal guardians (if the patient is &lt;18
                  years of age) must sign an Ethics or institutional Review Board approved consent
                  form indicating their awareness of the investigational nature and the risks of
                  this study. When appropriate, younger patients will be included in all
                  discussions in order to obtain assent.

               -  Adequate organ function: Patients should have adequate hepatic, renal, cardiac
                  and pulmonary function to undergo reduced intensity HCT based upon local
                  institutional guidelines, or at a minimum meet requirements noted in eligibility
                  checklist Appendix A-VIII_1. However, significant hepatic and pulmonary
                  dysfunction, if secondary to underlying LCH disease activity, will not exclude
                  patients from protocol enrollment and should be discussed with the National PI
                  Coordinator and the Coordinating Principal Investigator.

          -  Stratum V

               -  All patients with verified diagnosis of LCH and MRI findings consistent with
                  ND-CNSLCH irrespective of previous treatments (also those not registered to other
                  Strata ofLCH-IV).

               -  Patients with isolated tumorous CNS-LCH (including isolated DI with mass lesion
                  in the hypothalamus-pituitary axis). In patients with already established
                  diagnosis of LCH and radiologic finding of CNS lesions compatible with LCH, a
                  biopsy of the lesion is not obligatory. In all other cases a biopsy of the lesion
                  is needed for inclusion into the study

          -  Stratum VI

             -- Patients with newly diagnosed SS-LCH and localization other than &quot;multifocal
             bone&quot;,isolated tumorous CNS lesion, or isolated &quot;CNS-risk&quot; lesion.

          -  Stratum VII -- All patients registered in LCH IV (regardless of treatment) as long as
             consent for longterm follow-up has not been withheld.

        Exclusion Criteria:

          -  Stratum I

               -  Pregnancy (patients of child-bearing age must be appropriately tested before
                  chemotherapy)

               -  LCH-related permanent consequences (e.g. vertebra plana, sclerosing cholangitis,
                  lung fibrosis, etc.) in the absence of active disease

               -  Prior systemic therapy

          -  Stratum II

               -  Patients with progressive disease in risk organs

               -  Permanent consequences (e.g. sclerosing cholangitis, lung fibrosis, etc.) without
                  evidence of active LCH in the same organ or in any other locations

               -  No written consent of the patient or his/her parents or legal guardian

          -  Stratum III

               -  The presence of any of the following criteria will exclude the patient from the
                  study:

               -  Isolated sclerosing cholangitis without evidence of active hepatic LCH as the
                  only evidence of risk organ involvement.

               -  Inadequate renal function as defined by serum creatinine &gt; 3x normal for age

          -  Stratum IV

               -  Pulmonary failure (requiring mechanical ventilation) not due to active LCH.

               -  Isolated liver sclerosis or pulmonary fibrosis, without active LCH.

               -  Uncontrolled active life-threatening infection.

               -  Decreased renal function with a GFR of less than 50ml/1.73m2/min.

               -  Pregnancy or active breast feeding

               -  Failure to provide signed informed consent

          -  Stratum VI

               -  Patients with SS-LCH who have an isolated tumorous CNS lesion (they are eligible
                  for Stratum V),

               -  Patients with isolated &quot;CNS-risk&quot; or multifocal bone lesions (they are eligible
                  for Stratum I, Group 2)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Milen Minkov, MD, Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>Children's Cancer Research Institute / St. Anna Children's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlos Rodriguez-Galindo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>North American Consortium for Histiocytosis</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heidi M Clough, BSN</last_name>
    <phone>901-595-0362</phone>
    <email>Heidi.clough@stjude.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lane Faughnan, BSN</last_name>
    <phone>901-595-0364</phone>
    <email>Lane.faughnan@stjude.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Phoenix Children's Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Henry, MD</last_name>
      <email>mhenry@phoenixchildrens.com</email>
    </contact>
    <investigator>
      <last_name>Michael Henry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimo Stine, MD</last_name>
      <email>stinekimoc@uams.edu</email>
    </contact>
    <investigator>
      <last_name>Kimo Stine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rima Jubran, MD</last_name>
      <email>rjubran@chla.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Rima Jubran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Valley Children's Healthcare</name>
      <address>
        <city>Madera</city>
        <state>California</state>
        <zip>93636</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Samuel, MD</last_name>
      <email>DSamuel@valleychildrens.org</email>
    </contact>
    <contact_backup>
      <last_name>Faisal Razzaqi, MD</last_name>
      <email>FRazzaqi@valleychildrens.org</email>
    </contact_backup>
    <investigator>
      <last_name>David Samuel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Connecticut Children's Medical Center</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrea Orsey, MD</last_name>
      <email>aorsey@connecticutchildrens.org</email>
    </contact>
    <investigator>
      <last_name>Andrea Orsey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan Ladisch, MD</last_name>
      <email>sladisch@childrensnational.org</email>
    </contact>
    <contact_backup>
      <last_name>Jay Greenberg, MD</last_name>
      <email>jagreenb@childrensnational.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elias Zambidis, MD</last_name>
      <email>EZambid1@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Christine Pratilas, MD</last_name>
      <email>Cpratil1@jhmi.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Huang, MD</last_name>
      <phone>617-726-2737</phone>
      <email>mshuang@partners.org</email>
    </contact>
    <investigator>
      <last_name>Mary Huang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Degar, MD</last_name>
      <phone>617-632-6801</phone>
      <email>bdegar@partners.org</email>
    </contact>
    <investigator>
      <last_name>Barbara Degar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Richards, MD</last_name>
      <email>Michael.richards@childrensmn.org</email>
    </contact>
    <contact_backup>
      <last_name>Nathan Gossai, MD</last_name>
      <email>nathan.gossai@childrensmn.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Diamond, MD</last_name>
      <email>Steven.Diamond@hackensackmeridian.org</email>
    </contact>
    <contact_backup>
      <last_name>Burton Appel, MD</last_name>
      <email>Burton.appel@hackensackmeridian.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Cohen Children's Medical Center</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolyn Fein Levy, MD</last_name>
      <email>clevy4@northwell.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jeffery Lipton, MD</last_name>
      <email>jlipton@northwell.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Columbia University / Herbert Irving Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Luis Sulis, MD</last_name>
      <email>mls95@cumc.columbia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Julia Glade Bender, MD</last_name>
      <email>jg589@cumc.columbia.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Staten Island University Hospital</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Vaiselbuh, MD</last_name>
      <phone>718-226-6435</phone>
      <email>svaiselbuh@nshs.edu</email>
    </contact>
    <investigator>
      <last_name>Sarah Vaiselbuh`, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanie Comito, MD</last_name>
      <email>comitom@upstate.edu</email>
    </contact>
    <contact_backup>
      <last_name>Andrea Dvorak, MD</last_name>
      <email>dvoraka@upstate.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Jordan, MD</last_name>
      <phone>513-636-1773</phone>
      <email>Michael.jordan@cchmc.org</email>
    </contact>
    <contact_backup>
      <last_name>Ashish Kumar, MD</last_name>
      <phone>513-803-1631</phone>
      <email>ashish.kumar@cchmc.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Medical Universtiy of South Carolina/Hollings Cancer Center</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jacqueline Kraveka, DO</last_name>
      <phone>843-792-2957</phone>
      <email>kravekjm@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Jacqueline Kraveka, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Campbell, MD</last_name>
      <email>patrick.campbell@stjude.org</email>
    </contact>
    <investigator>
      <last_name>Patrick Campbell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Sacred Heart Children's Hospital</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefanos Intzes, MD</last_name>
      <email>stefanos.intzes@providence.org</email>
    </contact>
    <contact_backup>
      <last_name>Judy Felgenhauer, MD</last_name>
      <email>judy.felgenhauer@providence.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2014</study_first_submitted>
  <study_first_submitted_qc>July 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2014</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Langerhans cell histiocytosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Histiocytosis</mesh_term>
    <mesh_term>Histiocytosis, Langerhans-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>6-Mercaptopurine</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Indomethacin</mesh_term>
    <mesh_term>Cladribine</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

